AU2019255282B2 - Gabaa positive allosteric modulator compounds, methods of making, and uses thereof - Google Patents

Gabaa positive allosteric modulator compounds, methods of making, and uses thereof Download PDF

Info

Publication number
AU2019255282B2
AU2019255282B2 AU2019255282A AU2019255282A AU2019255282B2 AU 2019255282 B2 AU2019255282 B2 AU 2019255282B2 AU 2019255282 A AU2019255282 A AU 2019255282A AU 2019255282 A AU2019255282 A AU 2019255282A AU 2019255282 B2 AU2019255282 B2 AU 2019255282B2
Authority
AU
Australia
Prior art keywords
measured
xrpd pattern
parameters described
theta
pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019255282A
Other languages
English (en)
Other versions
AU2019255282A1 (en
Inventor
Jed Hubbs
Matthew TOCZKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocycle Therapeutics Inc
Original Assignee
Neurocycle Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocycle Therapeutics Inc filed Critical Neurocycle Therapeutics Inc
Publication of AU2019255282A1 publication Critical patent/AU2019255282A1/en
Application granted granted Critical
Publication of AU2019255282B2 publication Critical patent/AU2019255282B2/en
Priority to AU2024259803A priority Critical patent/AU2024259803A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Psychiatry (AREA)
AU2019255282A 2018-04-18 2019-04-17 Gabaa positive allosteric modulator compounds, methods of making, and uses thereof Active AU2019255282B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024259803A AU2024259803A1 (en) 2018-04-18 2024-11-07 GABAA positive allosteric modulator compounds, methods of making, and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659226P 2018-04-18 2018-04-18
US62/659,226 2018-04-18
PCT/US2019/027880 WO2019204446A1 (en) 2018-04-18 2019-04-17 Gabaa positive allosteric modulator compounds, methods of making, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024259803A Division AU2024259803A1 (en) 2018-04-18 2024-11-07 GABAA positive allosteric modulator compounds, methods of making, and uses thereof

Publications (2)

Publication Number Publication Date
AU2019255282A1 AU2019255282A1 (en) 2020-11-05
AU2019255282B2 true AU2019255282B2 (en) 2024-08-08

Family

ID=68239798

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019255282A Active AU2019255282B2 (en) 2018-04-18 2019-04-17 Gabaa positive allosteric modulator compounds, methods of making, and uses thereof
AU2024259803A Pending AU2024259803A1 (en) 2018-04-18 2024-11-07 GABAA positive allosteric modulator compounds, methods of making, and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024259803A Pending AU2024259803A1 (en) 2018-04-18 2024-11-07 GABAA positive allosteric modulator compounds, methods of making, and uses thereof

Country Status (14)

Country Link
US (3) US11542263B2 (enExample)
EP (1) EP3781566A4 (enExample)
JP (3) JP7449272B2 (enExample)
KR (2) KR20250057112A (enExample)
CN (2) CN121135719A (enExample)
AU (2) AU2019255282B2 (enExample)
BR (1) BR112020021104A2 (enExample)
CA (1) CA3096890A1 (enExample)
CL (1) CL2020002663A1 (enExample)
IL (1) IL278067A (enExample)
MX (2) MX2020010878A (enExample)
SG (1) SG11202010220QA (enExample)
TW (1) TW202012402A (enExample)
WO (1) WO2019204446A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020021104A2 (pt) * 2018-04-18 2021-02-23 Neurocycle Therapeutics, Inc compostos moduladores alostéricos positivos gabaa, métodos de produção e usos dos mesmos
CA3132810A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of fybromyalgia
JP2022553718A (ja) * 2019-10-22 2022-12-26 ニューロサイクル・セラピューティクス・インコーポレイテッド Ｇａｂａａ陽性アロステリック調節因子化合物、作成方法、およびその使用
CN120267677A (zh) * 2019-10-23 2025-07-08 纽罗塞克医疗公司 用gabaa受体调节剂的癫痫状况的治疗
US12233070B2 (en) * 2020-06-30 2025-02-25 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder
JP2025535716A (ja) * 2022-10-04 2025-10-28 エングレイル セラピューティクス，インコーポレーテッド Ｇａｂａａ受容体モジュレーターおよびその使用
WO2025175214A1 (en) * 2024-02-16 2025-08-21 Engrail Therapeutics, Inc. Methods of treating generalized anxiety disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008418A1 (en) * 2001-07-16 2003-01-30 Merck Sharp & Dohme Limited Imidazo-triazine derivatives as ligands for gaba receptors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2802343C2 (de) 1978-01-20 1982-04-22 Peter Prof. Dr.-Ing. Friderichs Latentwärmespeicher-Behälter
GB9813576D0 (en) * 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
CA2427779A1 (en) * 2000-11-10 2002-05-16 Merck Sharp & Dohme Limited Imidazo-triazine derivatives as ligands for gaba receptors
TWI248936B (en) * 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
JP2004170323A (ja) 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd 皮膚疾患治療剤のスクリーニング方法
WO2009021957A2 (en) 2007-08-14 2009-02-19 Novartis Ag Tricyclic heterocyclic compounds as gaba a modulators
TWI472529B (zh) * 2008-05-21 2015-02-11 Incyte Corp ２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法
WO2011011712A1 (en) * 2009-07-24 2011-01-27 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
AU2014219855B2 (en) 2013-02-19 2017-09-28 Ono Pharmaceutical Co., Ltd. Trk-inhibiting compound
WO2015072853A1 (en) 2013-11-13 2015-05-21 Rjg Developments B.V. Treatment of herpes virus infection outbreaks
WO2017129801A1 (en) * 2016-01-27 2017-08-03 Universität Zürich Use of gabaa receptor modulators for treatment of itch
BR112020021104A2 (pt) * 2018-04-18 2021-02-23 Neurocycle Therapeutics, Inc compostos moduladores alostéricos positivos gabaa, métodos de produção e usos dos mesmos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008418A1 (en) * 2001-07-16 2003-01-30 Merck Sharp & Dohme Limited Imidazo-triazine derivatives as ligands for gaba receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Gauthier, Jr., D.R. et al.; J. Med. Chem., 70, 5938-5945 (2005); DOI: 10.1021/jo0507035 *
Russell, M.G.N. et al.; J. Med. Chem., 49, 1235-1238 (2006); DOI: 10.1021/jm051200u *

Also Published As

Publication number Publication date
BR112020021104A2 (pt) 2021-02-23
WO2019204446A1 (en) 2019-10-24
AU2024259803A1 (en) 2024-11-28
MX2020010878A (es) 2021-01-29
JP7449272B2 (ja) 2024-03-13
JP2025166011A (ja) 2025-11-05
CN112384513A (zh) 2021-02-19
KR102799156B1 (ko) 2025-04-21
KR20250057112A (ko) 2025-04-28
US11542263B2 (en) 2023-01-03
US20230139418A1 (en) 2023-05-04
JP2021522330A (ja) 2021-08-30
EP3781566A4 (en) 2022-06-22
CL2020002663A1 (es) 2021-06-11
IL278067A (en) 2020-11-30
AU2019255282A1 (en) 2020-11-05
SG11202010220QA (en) 2020-11-27
JP2024063136A (ja) 2024-05-10
US20210040103A1 (en) 2021-02-11
JP7721712B2 (ja) 2025-08-12
US20250034155A1 (en) 2025-01-30
EP3781566A1 (en) 2021-02-24
MX2024004400A (es) 2024-04-29
CA3096890A1 (en) 2019-10-24
TW202012402A (zh) 2020-04-01
CN121135719A (zh) 2025-12-16
US12134619B2 (en) 2024-11-05
KR20210011921A (ko) 2021-02-02

Similar Documents

Publication Publication Date Title
AU2019255282B2 (en) Gabaa positive allosteric modulator compounds, methods of making, and uses thereof
JP2026010061A (ja) ３－（イミダゾ［１，２－ｂ］ピリダジン－３－イルエチニル）－４－メチル－Ｎ－｛４－［（４－メチルピペラジン－１－イル）メチル］－３－（トリフルオロメチル）フェニル｝ベンズアミドおよびその一塩酸塩の結晶形
RU2577541C2 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА СОЕДИНЕНИЯ ПИРИМИДО [6, 1-а]ИЗОХИНОЛИН-4-ОНА
KR102442536B1 (ko) 리나글립틴 결정형 및 이의 제조방법
KR20140075703A (ko) 프리도피딘 하이드로클로라이드의 다형 형태
JP2026021408A (ja) Ｇａｂａａ陽性アロステリック調節因子化合物、作成方法、およびその使用
WO2023091974A2 (en) Salt and solid forms of (r)-1-(5-methoxy-1 h-indol-1-yl)-n,n-dimethylpropan-2-amine
US12617794B2 (en) GABAA positive allosteric modulator compounds, methods of making, and uses thereof
JP2020073523A (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
KR20170023019A (ko) 알츠하이머병의 치료를 위한 ｎ-[2-(6-플루오로-1ｈ-인돌-3-일)에틸]-3-(2,2,3,3-테트라플루오로프로폭시)벤질아민 히드로클로라이드의 신규한 다형체 형태

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)